This Article Appeared in a Journal Published by Elsevier. the Attached

Total Page:16

File Type:pdf, Size:1020Kb

This Article Appeared in a Journal Published by Elsevier. the Attached This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues. Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited. In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier’s archiving and manuscript policies are encouraged to visit: http://www.elsevier.com/copyright Author's personal copy General and Comparative Endocrinology 166 (2010) 409–416 Contents lists available at ScienceDirect General and Comparative Endocrinology journal homepage: www.elsevier.com/locate/ygcen Oral progestin induces rapid, reversible suppression of ovarian activity in the cat R.A. Stewart a,b,1, K.M. Pelican a,2, J.L. Brown a, D.E. Wildt a,*, M.A. Ottinger b, J.G. Howard a a Department of Reproductive Sciences, Center for Species Survival, Smithsonian’s National Zoological Park, Conservation & Research Center, Front Royal, VA 22630, USA b Department of Animal and Avian Sciences, University of Maryland, College Park, MD 20742, USA article info abstract Article history: The influence of oral progestin (altrenogest; ALT) on cat ovarian activity was studied using non-invasive Received 28 July 2009 fecal steroid monitoring. Queens were assigned to various ALT dosages: (1) 0 mg/kg (control; n = 5 cats); Revised 7 December 2009 (2) 0.044 mg/kg (LOW; n = 5); (3) 0.088 mg/kg (MID; n = 6); or (4) 0.352 mg/kg (HIGH; n = 6). Fecal estro- Accepted 28 December 2009 gen and progestagen concentrations were quantified using enzyme immunoassays for 60 days before, Available online 4 January 2010 38 days during and 60 days after ALT treatment. Initiation of follicular activity was suppressed in all cats during progestin treatment, whereas controls continued to cycle normally. Females (n = 6) with elevated Keywords: fecal estrogens at treatment onset completed a normal follicular phase before returning to baseline and Cat remained suppressed until treatment withdrawal. All cats receiving oral progestin re-initiated follicular Progestin Altrenogest activity after treatment, although MID cats experienced the most synchronized return (within 10– Ovarian suppression 16 days). Mean baseline fecal estrogens and progestagens were higher (P < 0.05) after treatment in HIGH, Fecal hormone monitoring but not in LOW or MID cats compared to pre-treatment values. The results demonstrate that: (1) oral pro- Estrous cycle gestin rapidly suppresses initiation of follicular activity in the cat, but does not influence a follicular phase that exists before treatment initiation; and (2) queens return to normal follicular activity after pro- gestin withdrawal. This study provides foundational information for research aimed at using progestin priming to improve ovarian response in felids scheduled for ovulation induction and assisted breeding. Ó 2010 Elsevier Inc. All rights reserved. 1. Introduction attempts have failed in the fishing cat (Bauer et al., 2004) and Pallas’ cat (Brown et al., 2002). Endangered felids have benefited from assisted reproduction Although a clear etiology for pregnancy failure after AI has not strategies designed to maintain or increase genetic diversity in been established, one contributor appears to be inconsistent ovar- small populations managed ex situ (Wildt and Roth, 1997; Wildt ian response after exogenous gonadotropins are used to stimulate et al., 2010). Approaches such as artificial insemination (AI) and the ovary before insemination (Howard and Wildt, 2009). Most fe- in vitro fertilization/embryo transfer can improve reproductive effi- lid ovulation induction protocols involve administering a species- ciency in rare cat species when natural breeding fails (Howard, specific dosage of equine chorionic gonadotropin (eCG) to initiate 1999; Swanson, 2003; Howard and Wildt, 2009). A laparoscopic follicular growth followed by human chorionic gonadotropin intrauterine AI technique has been successful, producing offspring (hCG) to complete meiotic maturation of the oocyte(s) and ovula- in the cheetah (Howard et al., 1992, 1997), clouded leopard tion (Howard, 1999). However, eCG can stimulate ovulation if gi- (Howard et al., 1996, 1997), tiger (Donoghue et al., 1993), puma ven during estrus, and hCG has folliculogenic properties in the (Barone et al., 1994), leopard cat (Wildt et al., 1992), snow leopard cat (Swanson et al., 1997). Thus, when eCG and hCG are adminis- (Roth et al., 1997a), tigrina (Swanson and Brown, 2004) and ocelot tered in tandem at random intervals in the estrous cycle, a hy- (Swanson et al., 1996b). However, pregnancy success is variable per-follicular state can occur (Swanson et al., 1996a), resulting in across species. AI efficiency is 45% in the cheetah (Howard abnormally high and protracted circulating estrogen profiles, re- et al., 1997), but success remains low (<5%) in the clouded leopard duced embryo quality and delayed embryo transport through the (Howard et al., 1997) and tiger (Graham et al., 2006), and multiple oviduct (Roth et al., 1997b; Graham et al., 2000). Felids are also notorious for exhibiting unusually high variation in ovulation ‘type’. Traditionally considered induced ovulators (Wildt et al., 1980), more recent investigations have confirmed spontaneous * Corresponding author. Fax: +1 540 635 6506. ovulation in laboratory-housed domestic cats (Lawler et al., E-mail address: [email protected] (D.E. Wildt). 1993; Gudermuth et al., 1997; Graham et al., 2000; Pelican et al., 1 Present address: Center for the Integrative Study of Animal Behavior, Indiana 2005) and certain non-domestic species, including the fishing cat, University, Bloomington, IN, USA. 2 Present address: Department of Veterinary Population Medicine, College of margay and clouded leopard (Brown et al., 2001; Moreira et al., Veterinary Medicine, University of Minnesota, St. Paul, MN, USA. 2001; Brown, 2006). Spontaneous ovulation further complicates 0016-6480/$ - see front matter Ó 2010 Elsevier Inc. All rights reserved. doi:10.1016/j.ygcen.2009.12.016 Author's personal copy 410 R.A. Stewart et al. / General and Comparative Endocrinology 166 (2010) 409–416 artificial control of the ovary because corpora lutea presence and in a domestic cat (Brown et al., 1994; Pelican et al., 2005). We parallel elevations in circulating progesterone reduce (or prevent) presumed that suppression for this interval would ensure lysis of the effective use of exogenous gonadotropins (Pelican et al., existing corpora lutea (if present) and promote sufficient ovarian 2006, 2008). quiescence by the end of treatment. Each cat received two different For assisted reproduction to be maximally efficient in felids, a dosages (in Trial 1 versus Trial 2) separated by an 8-month inter- ‘quiescent’ ovary at the time of ovulation induction is required. val. Resumption of normal follicular activity after Trial 1 was con- This environment increases the chance for a consistent and uni- firmed by fecal hormone analyses before beginning Trial 2. Cats form folliculogenic response to ovarian stimulation while greatly were randomly assigned to the two treatments in a balanced order diminishing the risk of an altered endocrine milieu. This concept to avoid ‘carry-over’ effects between the consecutive trials. appears especially valid in felids as illustrated by the cheetah, a Altrenogest oral suspension (Regu-MateÒ; 2.2 mg/ml; Intervet consistent induced ovulator with frequent periods of acyclicity Inc., Millsboro, DE) was stored at room temperature (21 °C) in (Brown et al., 1996). Both these traits no doubt have contributed an opaque container. During each trial, the progestin was mixed to ‘normal’ ovulation numbers post-eCG/hCG and a comparatively into 5 g of wet food (FriskiesÒ; Nestlé Purina PetCare Co.) and high incidence of AI success in the cheetah (Howard et al., 1992, administered daily for 38 consecutive days. In Trial 1, each cat 1997) as well as in another induced ovulator, the ocelot (Swanson was assigned to one of four ALT treatments: (1) 0 mg/kg (control; et al., 1996b). In non-felids that spontaneously ovulate, including wet food only; n = 3 cats); (2) 0.088 mg/kg (n = 3); (3) 0.176 mg/ domestic livestock (Lofstedt, 1988; Wood et al., 1992; Deligiannis kg (n = 3); or (4) 0.352 mg/kg (n = 4). Based on Trial 1 results, the et al., 2005) and wild ungulates (Monfort et al., 1993; Morrow 0.176 mg/kg treatment was removed from the experimental design et al., 2000), progestins are routinely administered prior to assisted and replaced with a new test dosage (0.044 mg/kg) to better refine breeding to temporarily suppress follicular activity and improve the lowest effective dosage. In Trial 2, each cat was assigned to one ovarian response. Although the progestins melengestrol acetate of four treatments: (1) 0 mg/kg (n = 2); (2) 0.044 mg/kg (n = 5); (3) (MGA), megestrol acetate and medroxyprogesterone acetate are 0.088 mg/kg (n = 3); or (4) 0.352 mg/kg (n = 2). well-known contraceptive agents in felids (Romatowski, 1989; Munson, 2006), their ability to temporarily suppress ovarian activ- 2.3. Fecal hormone extraction ity for the purpose of assisted reproduction has not been investi- gated. Our laboratory confirmed the efficacy of the progestin Over the course of the study, fecal samples were collected daily, levonorgestrel (NorplantÒ) delivered as an implant for short-term sealed in plastic bags labeled with the individual’s name/date and suppression of ovarian activity in the cat (Pelican et al., 2005). stored at À20 °C. Fecal aliquots from 60 days before, 38 days dur- However, this approach requires anesthesia to insert and remove ing and 60 days after each treatment period were extracted to the implants and, more importantly, results in variable returns to quantify estrogen and progestagen concentrations using assays ovarian cyclicity after implant removal (ranging from 2 weeks validated for the domestic cat (Brown et al., 1994).
Recommended publications
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (Anti-)Androgenic Activities in Aquatic Environments?
    Environmental Pollution 242 (2018) 417e425 Contents lists available at ScienceDirect Environmental Pollution journal homepage: www.elsevier.com/locate/envpol Do progestins contribute to (anti-)androgenic activities in aquatic environments?* * Pavel Sauer , Adam Borík, Oksana Golovko, Roman Grabic, Andrea Vojs Stanov a, Olga Valentova, Alzbeta Stara, Marie Sandova, Hana Kocour Kroupova University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture and Biodiversity of Hydrocenoses, Research Institute of Fish Culture and Hydrocenoses, Zati sí 728/II, 389 25 Vodnany, Czech Republic article info abstract Article history: Unknown compounds with (anti-)androgenic activities enter the aquatic environment via municipal Received 21 May 2018 wastewater treatment plants (WWTPs). Progestins are well-known environmental contaminants capable Received in revised form of interfering with androgen receptor (AR) signaling pathway. The aim of the present study was to 28 June 2018 determine if 15 selected progestins have potential to contribute to (anti-)androgenic activities in Accepted 30 June 2018 municipal wastewaters and the respective recipient surface waters. AR-specific Chemically Activated Available online 4 July 2018 LUciferase gene eXpression bioassay in agonistic (AR-CALUX) and antagonistic (anti-AR-CALUX) modes and liquid chromatography tandem atmospheric pressure chemical ionization/atmospheric photoioni- Keywords: Progestagens zation with hybrid quadrupole/orbital trap mass spectrometry operated in high resolution product scan Solid-phase extraction mode (LC-APCI/APPI-HRPS) methods were used to assess (anti-)androgenic activity and to detect the Target analysis target compounds, respectively. The contribution of progestins to (anti-)androgenic activities was Sample acidification evaluated by means of a biologically and chemically derived toxicity equivalent approach.
    [Show full text]
  • Regu-Mate® (Altrenogest) Management Practices and Potential for Exposure in Equine Care Givers
    Regu-Mate® (altrenogest) Management Practices and Potential for Exposure in Equine Care Givers A thesis submitted by Ariel Newman In partial fulfillment of the requirements for the degree of Master of Science in Civil and Environmental Engineering TUFTS UNIVERSITY August 2013 Advisers: Anne Marie C. Desmarais, Mark Woodin and Brett Gaby DVM ABSTRACT Regu-Mate, the synthetic progesterone altrenogest, is used to control estrus in horses. Equine caregivers handling Regu-Mate may be exposed through accidental exposure or inadequate safety procedures. This exposure can result in adverse health effects including menstrual cycle changes, uterine/abdominal cramping, headaches and prolonged pregnancy. Surveys asked equine caregivers about Regu-Mate handling procedures, skin exposure to the drug, symptoms associated with exposure to the drug, and general background information. I analyzed results through descriptive statistics. Most respondents do not take sufficient safety precautions when handling Regu-Mate. Respondents most commonly use rubber/latex gloves or do not wear gloves when handling the drug and/or use a non-locking syringe to withdraw the medication. Respondents become complacent, taking fewer precautions the longer and more often they handle Regu-Mate. I developed a risk communication program that outlines the important safe handling discussion topics between veterinarians and clients and recommends a periodic check- in to evaluate a facility’s procedures. ii ACKNOWLEDGMENTS I would like to express my sincerest gratitude to Anne Marie
    [Show full text]
  • Depo-Provera Medroxyprogesterone
    DEPO-PROVERA® (MEDROXYPROGESTERONE) – Does this Medication Block Estrus in Mares? Patrick M. McCue DVM, PhD, Diplomate American College of Theriogenologists Horse owners, trainers, and veterinarians are mg of medroxyprogesterone as an intra- all looking for easy, inexpensive, and muscular injection, and then received 400 effective methods to block behavioral estrus mg once per week for an additional 5 weeks. in performance mares. Some mares are more This dose and treatment frequency were difficult to train or exhibit performance issues purposely chosen to be even higher that when in heat. A number of medications and commonly used in mares to suppress estrus. management strategies have been used over the years to prevent estrus in mares. This The goal was to compare the effect of article is the first in a series on the efficacy of medroxyprogesterone with that of a placebo medications or techniques used in mares to treatment, which should not alter the estrous suppress heat. cycle, and altrenogest, a medication known to suppress estrus. Depo-Provera® is the brand name of the synthetic progestin hormone medroxy- Mares were teased individually once per day progesterone. Depo-Provera® is used in by a stallion and the response recorded. human medicine as a method of birth control. Ultrasound examinations were performed Medroxyprogesterone has been administered three times per week and then daily when a to performance mares with the intention of follicle greater than 35 mm in diameter was blocking behavioral estrus. detected. The size of the pre-ovulatory follicle and day of ovulation was noted. In A controlled study was recently performed addition, blood samples were collected for to test the efficacy of medroxyprogesterone analysis of luteinizing hormone (LH) and in suppressing estrus in mares.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • AMRI India Pvt
    WE’VE GOT API DEVELOPMENT AND MANUFACTURING DOWN TO AN EXACT SCIENCE API Commercial Product Catalogue PRODUCT CATALOGUE API Commercial US EU Japan US EU Japan API Name Site CEP India China API Name Site CEP India China DMF DMF DMF DMF DMF DMF Rozzano Quinto de Adenosine Betaine Citrate Anhydrous Bon Encontre, France A Stampi, Italy • Betametasone-17,21- Alcaftadine Valladolid, Spain Valladolid, Spain • Dipropionate Sterile • Alclometasone-17,21- Valladolid, Spain Betamethasone Acetate Valladolid, Spain Dipropionate • • • Altrenogest Valladolid, Spain • • Betamethasone Base Valladolid, Spain Aminobisamide HCl Rensselaer, US Betamethasone Benzoate Valladolid, Spain Amphetamine Aspartate Betamethasone Valerate Rensselaer, US Valladolid, Spain Monohydrate Milled • Acetate Betamethasone-17,21- Amphetamine Sulfate Rensselaer, US Valladolid, Spain • Dipropionate • • • • Rozzano Quinto de Argatroban Betamethasone-17-Valerate Valladolid, Spain Stampi, Italy • • • • Betamethasone-21- Atenolol Aurangabad, India Valladolid, Spain • • • Phosphate Disodium Salt • • Rozzano Quinto de Bromfenac Monosodium Atracurium Besylate Lodi, Italy Stampi, Italy • Salt Sesquihydrate • • Rozzano Quinto de Atropine Sulfate Grafton, US Bromocriptine Mesylate • Stampi, Italy • • • Rozzano Quinto de Azelastine HCl Budesonide Valladolid, Spain Stampi, Italy • • • • • Rozzano Valleambrosia, Aztreonam (not sterile) Budesonide Sterile Valladolid, Spain Italy • • • • B Bamifylline HCl Bon Encontre, France • C Capecitabine Lodi, Italy • • Beclomethasone-17,21- Valladolid, Spain
    [Show full text]
  • Residues of Medroxyprogesterone Acetate Detected in Sows at A
    This article was downloaded by: [Cirad-Dist Bib Lavalette] On: 22 November 2013, At: 10:04 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK Food Additives & Contaminants: Part A Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/tfac20 Residues of medroxyprogesterone acetate detected in sows at a slaughterhouse, Madagascar Vincent Porphyrea, Michel Rakotoharinomeb, Tantely Randriamparanyc, Damien Pognona, Stéphanie Prévostd & Bruno Le Bizecd a Centre de Coopération Internationale en Recherche Agronomique pour le Développement – CIRAD, Réunion, France b Direction of Veterinary Services, Ministry of Livestock Production, Antananarivo, Madagascar c National Laboratory of Veterinary Diagnostic, Antananarivo, Madagascar d Laboratoire d’Etude des Résidus et Contaminants dans les Aliments (LABERCA), Ecole Nationale Vétérinaire, Agroalimentaire et de l’Alimentation Nantes Atlantique (ONIRIS), Nantes, France Accepted author version posted online: 24 Sep 2013.Published online: 20 Nov 2013. To cite this article: Vincent Porphyre, Michel Rakotoharinome, Tantely Randriamparany, Damien Pognon, Stéphanie Prévost & Bruno Le Bizec , Food Additives & Contaminants: Part A (2013): Residues of medroxyprogesterone acetate detected in sows at a slaughterhouse, Madagascar, Food Additives & Contaminants: Part A, DOI: 10.1080/19440049.2013.848293 To link to this article: http://dx.doi.org/10.1080/19440049.2013.848293 PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • ARCI Uniform Classification Guidelines for Foreign Substances, Or Similar State Regulatory Guidelines, Shall Be Assigned Points As Follows
    DRUG TESTING STANDARDS AND PRACTICES PROGRAM. Uniform Classification Guidelines for Foreign Substances And Recommended Penalties Model Rule. January, 2019 (V.14.0) © ASSOCIATION OF RACING COMMISSIONERS INTERNATIONAL – 2019. Association of Racing Commissioners International 2365 Harrodsburg Road- B450 Lexington, Kentucky, USA www.arci.com Page 1 of 66 Preamble to the Uniform Classification Guidelines of Foreign Substances The Preamble to the Uniform Classification Guidelines was approved by the RCI Drug Testing and Quality Assurance Program Committee (now the Drug Testing Standards and Practices Program Committee) on August 26, 1991. Minor revisions to the Preamble were made by the Drug Classification subcommittee (now the Veterinary Pharmacologists Subcommittee) on September 3, 1991. "The Uniform Classification Guidelines printed on the following pages are intended to assist stewards, hearing officers and racing commissioners in evaluating the seriousness of alleged violations of medication and prohibited substance rules in racing jurisdictions. Practicing equine veterinarians, state veterinarians, and equine pharmacologists are available and should be consulted to explain the pharmacological effects of the drugs listed in each class prior to any decisions with respect to penalities to be imposed. The ranking of drugs is based on their pharmacology, their ability to influence the outcome of a race, whether or not they have legitimate therapeutic uses in the racing horse, or other evidence that they may be used improperly. These classes of drugs are intended only as guidelines and should be employed only to assist persons adjudicating facts and opinions in understanding the seriousness of the alleged offenses. The facts of each case are always different and there may be mitigating circumstances which should always be considered.
    [Show full text]